Protalix BioTherapeutics (PLX) Current Leases (2019 - 2026)

Protalix BioTherapeutics' Current Leases history runs 8 years deep, the most recent figure standing at $1.4 million for Q1 2026.

• On a quarterly basis, Current Leases rose 0.56% year-over-year to $1.4 million in Q1 2026; TTM through Mar 2026 was $1.4 million, a 0.56% increase from a year earlier, with the FY2025 full-year figure at $1.4 million, down 7.73% from the prior year.
• Current Leases improved to $1.4 million in Q1 2026 per PLX's latest filing, from $1.4 million in the prior quarter.
• Across five years, Current Leases topped out at $1.5 million in Q3 2024 and bottomed at $1.0 million in Q3 2022.
• The 5-year median for Current Leases is $1.4 million (2025), against an average of $1.3 million.
• Across the five-year window, Current Leases fell 19.03% in 2022 and surged 31.3% in 2023, its largest moves.
• Year by year, Current Leases stood at $1.1 million in 2022, then gained by 26.03% to $1.4 million in 2023, then grew by 6.46% to $1.5 million in 2024, then declined by 7.73% to $1.4 million in 2025, then increased by 3.54% to $1.4 million in 2026.
• Per Business Quant, the three latest PLX Current Leases figures stand at $1.4 million (Q1 2026), $1.4 million (Q4 2025), and $1.4 million (Q3 2025).